Global Cancer Pain Market Size, Trends, Opportunities, Innovations & Forecast till 2025
According to a new report published by KD
Market Insights, titled,"Cancer
Pain Market by Type and
Application: Global Opportunity Analysis and Industry Forecast, 2018 -
2025,"the global cancer pain market was valued at $5,285 million in 2017,
and is expected to reach $7,545 million by 2025, growing at a CAGR of
4.5% from 2018 to 2025.
Cancer pain is chronic in nature and is
commonly associated with cancer. It results from tissue damage, either due to
the disease itself or due to different treatments such as chemotherapy,
radiotherapy, or surgery. Cancer pain drugs are expected to exhibit significant
market growth during the forecast period due to growth in demand for the drugs,
surge in prevalence of cancer across the globe, increase in number of R&D
activities to develop ideal cancer pain medications, and rise in the unmet
needs for management of cancer pain.
Based on drug type, the global cancer pain
market is categorized into opioids, non-opioids, and nerve blockers. The
opioids segment was the major revenue contributor in 2017, and is anticipated
to remain dominant during the forecast period due to increase in the adoption
of opioids owing to rise in number of moderate to severe stage cancer patient
population.
According to disease indication, the market is
classified into lung cancer, colorectal cancer, breast cancer, prostate cancer,
blood cancer, and others. The lung cancer segment presently dominates the
market and is expected to remain dominant during the forecast period due to
increase in adoption of cancer pain medication for the treatment and rise in
prevalence of lung cancer, globally.
Key Findings of the Cancer Pain
Market:
- Based on drug type, the opioids segment is
expected to experience rapid growth in the market and is projected to grow at a
CAGR of 5.0% from 2018 to 2025.
- Based on disease indication, the lung cancer segment held more than one-fifth of the global market share in 2017 and is expected to remain dominant throughout the forecast period.
- Based on region, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 5.4% during the forecast period.
- Based on disease indication, the lung cancer segment held more than one-fifth of the global market share in 2017 and is expected to remain dominant throughout the forecast period.
- Based on region, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 5.4% during the forecast period.
North America accounted for more than
one-third of the global market share in 2017 and is expected to remain dominant
throughout the forecast period. This was attributed to the increase in demand
for cancer pain therapeutics, high prevalence of cancer, wide availability of
cancer pain drugs and trained medical professionals, and supportive
reimbursement policies in the healthcare system. Asia-Pacific is expected to
experience the highest growth rate during the forecast period majorly due to
surge in incidence of cancer, with increase in adoption of cancer pain drugs
for treatment of cancer.
About Us:
KD Market
Insights is one of the leading providers of market intelligence products
and services. We offer reports on over 10+ industries and update our collection
daily which helps our clients to access database of expert market insights on
global industries, companies, products, and trends.
Our
in-house research experts have a wealth of knowledge in their respective
domains. With KD Market Research, you always have the choice of getting
customized report free of cost (upto 10%). Our support team will help you
customize the report and scope as per your business needs. This ensures that
you are making the right purchase decision. Our clients list includes various
Fortune 500 companies and leading advisory firms.
Contact Us:
KD
Market Insights
90
State Street, Albany,
New
York, USA 12207
+1
(518) 300-1215
Comments
Post a Comment